	US 12,296,008 B2
	Pharmaceutical products and stable liquid compositions of IL-17 antibodies
Susanne Joerg, Binningen (CH); and Kathrin Serno-Schersch, Basel (CH)
Assigned to NOVARTIS AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Sep. 3, 2024, as Appl. No. 18/823,573.
Application 18/481,213 is a division of application No. 15/538,257, granted, now 11,801,300, issued on Oct. 31, 2023, previously published as PCT/IB2015/059836, filed on Dec. 21, 2015.
Application 18/823,573 is a continuation of application No. 18/481,213, filed on Oct. 4, 2023.
Claims priority of provisional application 62/095,210, filed on Dec. 22, 2014.
Prior Publication US 2024/0415961 A1, Dec. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01)

CPC A61K 39/39591 (2013.01) [C07K 16/244 (2013.01); C07K 2317/21 (2013.01)]

38 Claims

1. A stable liquid pharmaceutical composition comprising:

(a) about 25 mg/mL to about 175 mg/mL secukinumab;

(b) at least 2.5 mM methionine;

(d) a non-ionic stabilizer; and

(e) a surfactant;

wherein the composition has a pH of about 5.2 to about 6.2.